NCT05429021View on ClinicalTrials.gov

IMM-BCP-01 in Mild to Moderate COVID-19

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions
SARS-CoV2 InfectionCOVID-19
Interventions
DRUG

IMM-BCP-01

Single dose of IMM-BCP-01

DRUG

Placebo

Placebo matching single dose of IMM-BCP-01

Trial Locations (3)

10029

Icahn School of Medicine at Mt. Sinai, New York

33014

Panax Clinical Research, Miami Lakes

90806

Ark Clinical Research, Long Beach

Sponsors

Lead Sponsor

Immunome, Inc.
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Immunome, Inc.

INDUSTRY